سعر لاروسوزت 20/10مجم 30 قرص 2024

Fixed-dose combination film-coated tablets of ezetimibe 10 mg and rosuvastatin 20 mg, pack of 30, by Al Esraa Pharmaceutical Optima (Egypt); lipid-lowering agent.

• Adjunct to diet to lower LDL-C / treat hypercholesterolemia when combination therapy is appropriate (component-level US indications for rosuvastatin and ezetimibe)Population: AdultsDailyMed (U.S. NLM)

• Rosuvastatin: headache, nausea, myalgia, asthenia, constipation. Ezetimibe alone or with statin: URTI, diarrhea, arthralgia, myalgia, fatigue.General active-ingredient information · DailyMed (U.S. NLM)

• Rosuvastatin: acute liver failure or decompensated cirrhosis; hypersensitivity to rosuvastatin.General active-ingredient information · DailyMed (U.S. NLM)
• Ezetimibe: hypersensitivity to ezetimibe; contraindications of any coadministered statin/fenofibrate apply.General active-ingredient information · DailyMed (U.S. NLM)

• Myopathy/rhabdomyolysis risk from rosuvastatin (higher at 40 mg, with interacting drugs, Asian ancestry, age ≥65, renal impairment).General active-ingredient information · DailyMed (U.S. NLM)
• Monitor liver enzymes as clinically indicated for both components; discontinue if persistent ≥3×ULN elevations or serious hepatic injury.International label, equivalent formulation · DailyMed (U.S. NLM)

• Rosuvastatin may cause fetal harm; discontinue when pregnancy is recognized. Ezetimibe: use only if benefit justifies fetal risk. Breastfeeding not recommended with rosuvastatin.General active-ingredient information · DailyMed (U.S. NLM)

• Ezetimibe: Inhibits intestinal absorption of cholesterol and related phytosterols (US Vytorin label).
• Rosuvastatin: Competitive inhibition of HMG-CoA reductase reduces hepatic cholesterol synthesis and increases LDL-receptor expression.